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Abstract: Allergic rhinitis (AR) is a chronic inﬂ  ammatory respiratory disease affecting 5%–50% 
of the worldwide population and its prevalence is increasing (Herman 2007). In addition, AR is 
associated with asthma and other co-morbidities such as conjunctivitis and sinusitis. The main 
symptoms are nasal congestion, rhinorrea, sneezing, itching, and post-nasal drainage induced 
after allergen exposure by an IgE-mediated inﬂ  ammation of the membranes lining the nose. AR 
is not a life-threatening disease, but it has been shown to have a signiﬁ  cant impact on quality 
of life. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines propose a classiﬁ  ca-
tion of AR in intermittent and persistent, each graded as mild or moderate-severe, and provide 
a stepwise approach to the treatment. Inhaled steroids and antihistamine are the main tools in 
AR therapy but more safe and effective drugs are, however, needed. Inhaled steroid ciclesonide 
appears to be safe and effective.
Keywords: ciclesonide, allergic rhinitis, asthma, quality of life.
The burden of allergic rhinitis: the patient’s 
perspective
Allergic rhinitis is a global health problem that causes major illness and disability 
worldwide. Allergic rhinitis (AR) affects social life, sleep, school, and work. The 
economic impact of allergic rhinitis is often underestimated because the disease does 
not induce elevated direct costs. The indirect costs are, however, substantial. It is 
now recognized that allergic rhinitis comprises more than the classical symptoms 
of sneezing, rhinorrhea, and nasal obstruction. It is associated with impairments 
in how patients function in day-to-day life (Kirmaz et al 2005). It has been known 
for a long time that having an allergic reaction causes signiﬁ  cant fatigue and mood 
changes (Marshall et al 2002), some impairment of cognitive function (Marshall et al 
2000; Kremer et al 2002), and depression and anxiety (Cuffel et al 1999; Bavbek 
et al 2002). Impairment of quality of life, and work and school performance is 
common, particularly in patients with severe symptoms. These aspects of quality-
of-life impairment in AR should be quantiﬁ  ed using two types of tools for HRQL 
assessment – generic and speciﬁ  c questionnaires (Meltzer 2001; Gerth Van Wijk 
2003; Leong et al 2005).
The available treatments
Current pharmacology treatment for AR includes antihistamines, decongestants, anti-
cholinergic agents, intranasal cromolyn, leukotriene modiﬁ  ers and inhaled steroids. The 
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2007) suggest 
a stepwise approach to AR treatment.
In mild intermittent rhinitis, oral or intranasal anti-H1, intranasal decongestants, 
and oral decongestants (not in children) are suggested. For moderate-severe intermit-
tent rhinitis and mild persistent rhinitis, the suggested options (not in preferred order) Therapeutics and Clinical Risk Management 2008:4(2) 354
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are oral or intranasal anti-H1, oral anti-H1 + decongestant, 
intranasal CS, and chromones.
Moderate-severe persistent rhinitis requires intranasal CS 
as a ﬁ  rst line treatment and, in case of major blockage, to add 
short course of oral CS or decongestant; if symptoms persists 
it should be useful to add oral anti-H1 (± decongestants) and 
or ipratropium.
In accordance with ARIA guidelines (ARIA 2007), 
therapy with intranasal corticosteroid is recommended as 
ﬁ  rst-line prescription treatment in all the cases of AR with 
the exception of mild intermittent. Speciﬁ  c immunotherapy 
represents the unique treatment able not only to improve 
symptoms and quality of life but also to modify the disease 
progression.
The new treatment options
Monoclonal anti-IgE antibody
The recombinant, humanized, monoclonal anti-IgE antibody 
(omalizumab) forms complexes with free IgE, blocking its 
interaction with mast cells and basophils, and lowering (ARIA 
2007) free IgE levels in the circulation (Holgate et al 2005). 
In a large pivotal trial, omalizumab decreased serum-free IgE 
levels and provided clinical beneﬁ  t in a dose-dependent fashion 
in patients with seasonal allergic rhinitis (Linna et al 1992; 
Kaliner 2004). In adults and adolescents, omalizumab was 
found to decrease all nasal symptoms and to improve RQLQ 
in patients with rhinitis induced by birch and ragweed pollens 
as well as in those with sensitization to outdoor allergens 
(Adelroth et al 2001; Chervinsky et al 2003). Moreover, the 
treatment was safe and well tolerated (Berger et al 2003; Nayak 
et al 2003). The clinical beneﬁ  t of treatment with omalizumab 
is associated with an anti-inﬂ  ammatory effect on cellular mark-
ers in blood and nasal tissue (Plewako et al 2002; Bez et al 
2004) as well as with a reduction in mast cell FcεRI expression 
and function (Beck et al 2004). Omalizumab inhibits allergen 
challenge-induced nasal response (Hanf et al 2004).
New inhaled steroids
The relative efﬁ  ciency of this treatment compared to H1-
antihistamines and intranasal glucocorticosteroids needs to 
be established and a thorough cost/efﬁ  cacy analysis should 
be performed.
New inhaled steroids such as ciclesonide, appear to be 
promising. Ciclesonide, administered as an inactive parent 
compound that is metabolized by endogenous esterases in 
the upper and lower airways to the pharmacologically active 
metabolite, has shown to be effective, safe and, accordingly 
to once-daily administration, liked by patients.
From available glucocorticosteroids 
to ciclesonide
The goals of corticosteroid therapy are to maximize efﬁ  cacy, 
minimize potential systemic adverse effects, and improve 
patient adherence. Factors that will potentially improve 
adherence to treatment and differentiate the inhaled corti-
costeroids are dosing, regimen, patient preference and cost-
effectiveness (Dupclay and Doyle 2002; Herman 2007).
The commercially available inhaled corticosteroids (ICS) 
for AR treatment are beclomethasone dipropionate (BDP), 
budesonide (BUD), ﬂ  unisolide (FLU), ﬂ  uticasone propionate 
(FP), mometasone furoate (MF), and triamcinolone acetonide 
(TA); most of these are also available as nasal sprays for the 
treatment of AR. There is no longer any doubt about their 
effectiveness in both asthma and rhinitis. Since ICS are 
widely used in both adults and children, the issue of safety 
and the risk/beneﬁ  t ratio assumes a primary importance 
(Passalacqua et al 2000).
Treatment with glucocorticosteroids is the most efﬁ  ca-
cious medication for AR. The rationale for therapy using 
glucocorticosteroids can be summarized by their anti-
inﬂ  ammatory action and by their capacity to reduce nasal 
mucosa hyperreactivity (ARIA 2007). These medications 
are effective in improving all symptoms caused by allergic 
reaction to nasal and bronchial mucosa. For this reason, ICS 
are the most appropriate ﬁ  rst-line treatment, as they are more 
effective than any other treatment (Berger et al 2005; Bhatia 
et al 2005; ARIA 2007).
Mechanism of action of ICS
ICS are widely used and prescribed in both adults and chil-
dren, usually in long-term treatments. Therefore, the safety 
of these drugs is of some importance for both general prac-
titioners and specialists. The mechanism of action of gluco-
corticosteroids is directed to speciﬁ  c nuclear receptors, which 
induce and modulate the transcription of speciﬁ  c target genes. 
These genes encode for cytokines, lipocortin-1, endothelin, 
b-adrenoceptors, iNOS, endopeptidases, and so on. Several 
transcription factors are involved in this mechanism (Carson-
Jurica et al 1990; Munk et al 1990; Funder 1993; Barnes and 
Adcock 1993; Smith and Toft 1993; Barnes 1996). ICS exert 
their clinical and anti-inﬂ  ammatory actions depending on 
a wide range of variables, including the status of the nasal 
and bronchial wall (Laitinen 1994; Barnes 1995; Kraft et al 
1996), the pharmacodynamic-pharmacokinetic properties of 
the drug (Andersson and Ryrfeldt 1984; English et al 1994; 
Miller-Larson et al 1994; Lipworth 1995; Johnson 1996), the 
delivery system (Brown et al 1990; Selroos and Halme 1991; Therapeutics and Clinical Risk Management 2008:4(2) 355
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Smith et al 1995; Pedersen 1996), the patient’s cooperation 
(Toogood et al 1984; Pedersen et al 1986; Lindgren et al 1987; 
Newman et al 1991), and the dosage regimen (Munch et al 
1982; Pincus et al 1995; van Schayck et al 1995; Bernstein 
et al 2004). These factors also determine the severity and 
frequency of side-effects (Passalacqua et al 2000).
Side-effects
The occurrence and severity of these side-effects depend, as 
mentioned above, upon a large number of variables, including 
the characteristics of the drug (lipophilicity, pharmacokinet-
ics, and pharmacodynamics) and the mode of administration 
(for example, dose, delivery system, coordination).
Intranasal corticosteroids are highly effective; neverthe-
less, they are not completely devoid of systemic effects. Thus, 
care has to be taken, especially in children, when prescribing 
long-term treatments.
According to the available controlled studies, some 
effects on the hypothalamic-pituitary-adrenal axis (HPAA) 
and bone metabolism are detectable with high doses of ICS. 
Indeed, the effects on the HPAA and bone metabolism are 
measurable only by means of biochemical parameters; their 
clinical signiﬁ  cance is still unknown and probably extremely 
small compared to the beneﬁ  t achieved. Exogenous steroids, 
through negative feedback, suppress corticotrophin secretion, 
thus leading to adrenal cortex atrophy and to subsequent 
decrease of cortisol secretion; in fact long-term treatment 
with oral corticosteroids may result in signiﬁ  cant suppression 
of the HPAA. The free urinary cortisol over 24 h appears to 
be a practical and reliable index of HPAA interaction, since 
it provides a global evaluation of the adrenal function, and is 
not inﬂ  uenced by circadian changes in cortisol blood levels, 
but it is difﬁ  cult to demonstrate its clinical counterpart and 
its clinical signiﬁ  cance: in the controlled studies, no sign or 
symptom of adrenal failure was described.
Oral corticosteroids may induce osteoporosis and increase 
the risk of fractures in adult patients, reducing intestinal 
calcium absorption and enhancing its renal excretion; these 
actions result in compensatory secretion of parathormone, 
bone resorption, and increased activity of osteoclasts. 
Secondly, corticosteroids inhibit osteoblastic activity and 
the synthesis of osteocalcin. Thirdly, steroids reduce the 
synthesis of adrenal cortex-derived oestrogens. This last 
ﬁ  nding partly explains the increased risk of osteoporosis in 
postmenopausal women.
Although certain effects of ICS on bone metabolism 
are detectable, they are evident only by means of labora-
tory assessment, when high doses are used. In general, 
experimental evidence does not support an increased risk 
of osteoporosis or pathologic fractures in either adults or 
children. No change in bone density was detectable in adult 
patients taking ICS at high dosages (BUD or BDP 800 
mg/day) for up to 18 months.
Some data suggest that high doses of ICS can affect 
short-term growth in children, but this effect is certainly 
less signiﬁ  cant than that due to uncontrolled asthma. Growth 
retardation was seen only in children taking oral steroids. The 
available data suggest that short-term growth may be affected 
by high doses of ICS, but speed of growth and stature seem 
to depend strictly on the degree of asthma control. However 
this potential systemic side-effect imposes cautious use in 
children: the lowest effective dose must be used, and stature 
should be regularly monitored.
No signiﬁ  cant effect on glucose metabolism has been 
shown for ICS, even with high doses. An increase in neutro-
phil counts in the peripheral blood of patients taking ICS has 
been noted. Some local side-effects have also been described. 
Since local application of corticosteroids may cause dermal 
atrophy, the possibility of mucosal atrophy and epistaxis 
by long-term use of intranasal steroids has been thoroughly 
investigated. Furthermore, the data indicated that some of 
the adverse events such as irritation, crusting, itching, and 
stinging may be due to the propellant used in older formula-
tions rather than to the active drug.
Cutaneous side-effects may be of some relevance in the 
elderly, such as skin thinning and increased capillary fragil-
ity, especially in women, using high doses of ICS for long 
periods. Neurologic and ocular adverse events have to be 
considered anecdotal. In pregnant women, when indicated, 
ICS should be used at the lowest effective dose. BDP, for 
which more data are available, should be preferred; neverthe-
less, no actual teratogenicity in men has ever been reported. 
No speciﬁ  c study has been conducted on ICS and lactation 
(Passalacqua et al 2000).
Ciclesonide
Double blind, placebo-controlled studies on budesonide 
(Creticos et al 1998; Andersson et al 2000; Day et al 2000, 
2001), ﬂ  uticasone propionate (Nathan et al 1991; Dolovich 
et al 1994; LaForce et al 1994 Foresi et al 1996), mometa-
sone fuorate (Bronsky et al 1997; Berkowitz et al 1999a, b; 
Gawchik et al 2003), and triamcinolone acetonide (Munk 
et al 1996; Settipane et al 2002) have shown that once-daily 
administration of these ICS are well tolerated and more effec-
tive than placebo in the treatment of seasonal AR (SAR) and 
perennial AR (PAR) (Herman 2007).Therapeutics and Clinical Risk Management 2008:4(2) 356
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Ciclesonide is a new-generation corticosteroid with 
previously demonstrated efﬁ  cacy in the treatment of asthma 
when delivered through a metered-dose inhaler. Ciclesonide 
is also currently in clinical development as an intranasal 
formulation for use in the treatment of AR.
Pharmacodynamics and pharmacokinetics
The ciclesonide molecule has a chiral center in the acetal 
side chain. The two epimers of the compound are clearly 
different in their receptor afﬁ  nities and metabolization rates. 
The R-epimer has a considerably higher binding afﬁ  nity to 
the glucocorticoid receptor as compared to the S-epimer, 
and therefore only R-epimer is developed for clinical use 
(Schmidt et al 1999).
Ciclesonide is administered as an inactive parent com-
pound that is metabolized by endogenous esterases in the 
upper and lower airways to the pharmacologically active 
metabolite desisobutyryl-ciclesonide (des-CIC). In vitro 
studies in rat lung have shown that esteriﬁ  cation of des-CIC, 
working as a pool of active drug, may lead to durable anti-
inﬂ  ammatory activity (Dietzel et al 2001; Nave et al 2005; 
Wingertzahm et al 2005; Ratner et al 2006a).
Advantages of on-site activation include targeted acti-
vation in the lung, minimal systemic adverse effects, and 
minimal oropharyngeal side effects (Ukena 2005).
Low oral bioavailability (oral bioavailability of des-CIC 
is approximately 1%), high protein binding (99%) and high 
hepatic clearance (396 L/h) contribute to the favorable safety 
proﬁ  le of ciclesonide.
Clinical trials
Administration and dosage
The intranasal administration of ciclesonide at recom-
mended doses results in negligible serum concentrations of 
ciclesonide. However, the known active metabolite (des-
ciclesonide) is detected in the serum of some patients after 
nasal inhalation of ciclesonide.
In healthy adults treated for 2 weeks with 50–800 µg 
of ciclesonide nasal spray daily (n = 6 in each treatment 
group), the peak serum concentrations of des-ciclesonide 
in all subjects were found to be below 30 pg/mL. Among 
those treated with 800 µg and 400 µg daily, 100% and 67% 
had detectable levels of des-ciclesonide, respectively. With 
daily doses of 200 µg or less, detectable serum levels of 
des-ciclesonide were not observed.
In pediatric subjects treated with 25–200 µg of ciclesonide 
nasal spray daily, serum concentrations of des-ciclesonide 
were less than 45 pg/mL, with the exception of one value 
of 64.5 pg/mL. In a 12-week study, in children aged from 
6 to 11 with perennial allergic rhinitis, des-ciclesonide was 
detected in 50% of subjects treated with 200 µg and in 5% 
of those treated with 100 µg ciclesonide nasal spray daily. In 
a 6-week study, in children aged from 2 to 5 with perennial 
allergic rhinitis, des-ciclesonide was detected in 41%, 22%, 
and 13% of subjects treated with 200 µg, 100 µg, and 25 µg 
ciclesonide nasal spray daily, respectively.
Following intravenous administration of 800 µg of 
ciclesonide, the volumes of distribution of ciclesonide and 
des-ciclesonide were approximately 2.9 L/kg and 12.1 
L/kg, respectively. The percentage of ciclesonide and des-
ciclesonide bound to human plasma proteins averaged 99% 
each, with 1% of unbound drug detected in the systemic 
circulation. Des-ciclesonide is not signiﬁ  cantly bound to 
human transcortin.
Des-ciclesonide undergoes further metabolism in the liver 
to additional metabolites mainly by the cytochrome P450 
(CYP) 3A4 isozyme and to a lesser extent by CYP 2D6. The 
full range of potentially active metabolites of ciclesonide has 
not been characterized. After intravenous administration of 
14C-ciclesonide, 19.3% of the resulting radioactivity in the 
plasma is accounted for by ciclesonide or des-ciclesonide; 
the remainder may be a result of other, as yet, unidentiﬁ  ed 
multiple metabolites.
Following intravenous administration of 800 µg of 
ciclesonide, the clearance values of ciclesonide and des-
ciclesonide were high (approximately 152 L/h and 228 L/h, 
respectively).  14C-labeled ciclesonide was predominantly 
excreted via the feces after intravenous administration (66%) 
indicating that excretion through bile is the major route of 
elimination. Approximately 20% or less of drug related radio-
activity was excreted in the urine. The relative glucocorticoid 
receptor binding afﬁ  nity of des-CIC is 100-fold greater than 
that of ciclesonide. Des-ciclesonide has anti-inﬂ  ammatory 
activity with afﬁ  nity for the glucocorticoid receptor that is 
120 times higher than the parent compound. (ALTANA 
Pharma 2006).
Intranasal formulation
Ciclesonide for intranasal use is formulated in a hypotonic 
suspension, which has been shown in preclinical in vivo 
models to provide enhanced tissue uptake when compared 
with a traditional isotonic formulation. In addition, the intra-
nasal formulation of ciclesonide is preserved with potassium 
sorbate rather than benzalkonium chloride, which is used in 
many intranasal steroids (INSs). Benzalkonium chloride is 
believed to interfere with mucociliary transport and can lead Therapeutics and Clinical Risk Management 2008:4(2) 357
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to the development of hypersensitivity, rhinitis medicamen-
tosa, and neutrophil dysfunction.
Furthermore, benzalkonium chloride has a bitter taste that 
might compromise patient adherence (Graf 1999; Bernstein 
2000; Ratner et al 2006b).
Efﬁ  cacy and safety of ciclesonide
The once-daily intranasal administration of 200 µg of 
ciclesonide was shown to be effective for the treatment of 
seasonal AR, as demonstrated by a statistically signiﬁ  cant 
improvement from baseline compared with that seen in the 
placebo group in the primary efﬁ  cacy variable of the aver-
age of morning and evening reﬂ  ective TNSSs (total nasal 
symptom score) over days 1–14. Interestingly, although 
inhaled steroid products are typically perceived as having the 
greatest effect on nasal congestion, this study demonstrated 
that ciclesonide nasal spray showed a similar magnitude 
of effect on all four components of the TNSS, namely 
nasal congestion, rhinorrhea, nasal itching, and sneezing. 
Although no direct head-to-head trials between ciclesonide 
and other products have been performed to date, the indirect 
comparison across studies suggests that the treatment-effect 
size observed between ciclesonide and placebo is larger than 
that generally seen with montelukast, as well as nonsedating 
oral histamines, such as desloratadine, in the treatment of 
seasonal allergic rhinitis (Salmun and Lorber 2002; Nasonex 
2003). Additionally, the magnitude of effect observed in this 
study appears comparable with what had been previously 
demonstrated with mometasone in trials using a similar 
measurement scale (Dykewicz et al 2003).
The dosing posology was also assessed from the data of 
total nasal symptom score in another randomized, double-
blind, parallel-group, placebo-controlled, multicenter clinical 
trial (Ratner et al 2006b), which suggested that once-daily 
morning dosing is appropriate for ciclesonide nasal spray, 
and which could theoretically lead to increased compliance 
compared with drugs that are dosed twice or more daily.
In a multicenter, double-blind, randomized, placebo-
controlled, 2-week safety and efﬁ  cacy dose-ranging study, 
ciclesonide nasal spray (25–200 µg/day) was administered 
once daily for 14 days showing to be safe and effective in 
the treatment of SAR. Intranasal administration at doses of 
100–200 µg/day was associated with dose-related improve-
ments in nasal symptom relief compared with placebo and 
the 200 µg/day dose was numerically superior to 100 µg/day 
dose (Ratner et al 2006a).
Evidence supporting the 200 µg/day dose of ciclesonide 
nasal spray as the starting and maximum doses in adult 
patients was obtained from a post hoc test demonstrating 
that there is a dose-dependent increase in efﬁ  cacy and the 
200 µg/day dose of ciclesonide is the most effective dose 
studied for the amelioration of symptoms associated with 
SAR (Ratner et al 2006a).
Another study evaluated the efficacy and safety of 
intranasal ciclesonide, 200 µg once-daily, for the treatment 
of perennial allergic rhinitis (PAR). In this double-blind, 
randomized, placebo-controlled study, patients with at least 
2 years history of rhinitis received ciclesonide (n = 238) or 
placebo (n = 233) once daily for 6 weeks. In controlling 
daytime and nighttime, twice daily, nasal symptoms of PAR 
(runny nose, itchy nose, sneezing, and nasal congestion), 
ciclesonide was demonstrated to be superior to placebo. 
The comparable improvements in the morning and in the 
evening reﬂ  ective TNSS observed in this study support the 
rationale for a once-daily dosing regimen of ciclesonide in 
the treatment of PAR.
Ciclesonide, 200 µg once daily, was well tolerated in 
adult and adolescent patients with PAR and it was associ-
ated with a signiﬁ  cant reduction in correlated total nasal 
symptoms. Moreover, the frequency of adverse events in 
patients in ciclesonide group was similar to that of placebo. 
Ciclesonide treatment improved one measure of quality of 
life and was delivered with the convenience of once-daily 
dosing (Meltzer et al 2007).
The efﬁ  cacy and safety of ciclesonide in the treatment of 
allergic rhinitis have also been investigated in a double-blind, 
randomized, placebo-controlled, crossover trial involving 24 
subjects who were symptom free at the time of the study. A 
dose of 200 µg/nostril was administrated for 7 days. Subjective 
symptoms of obstruction, itching, and rhinorrhea improved 
from day 2 of treatment, and rhinal airﬂ  ow showed signiﬁ  cant 
improvement from day 5. Excellent tolerance at both local and 
systemic levels was seen (Meltzer and Derendorf 2006). These 
data conﬁ  rmed the results of previous clinical trials (Ratner 
et al 2004; Nave et al 2006; Meltzer et al 2007).
Results from ciclesonide clinical trials in allergic rhinitis 
are summarized in Table 1.
Ciclesonide and HPAA
Several studies have evaluated the potential suppressive 
effects of ciclesonide on HPAA function by measuring both 
sensitive and clinically relevant markers.
In a placebo-controlled, randomized, double-blind, 
4-period changeover equivalence study of healthy volunteers, 
ciclesonide (640 µg/day) was administered once daily, in the 
morning or evening, or half-dosed twice daily, to evaluate Therapeutics and Clinical Risk Management 2008:4(2) 358
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its effect on cortisol excrection and circadian serum cortisol 
rhythm. Patients were hospitalized after 6 days of ciclesonide 
treatment to measure 24-hour serum cortisol levels across 
the seventh day of treatment.
The 24-hour cortisol proﬁ  les obtained after ciclesonide 
treatment were equivalent to those observed in the placebo 
control group, because no signiﬁ  cant difference was seen in 
cortisol amplitude and acrophase (time to maximum). These 
results suggest that ciclesonide at a dose of up to 640 µg/day 
does not disrupt cortisol production or the normal diurnal 
rhythm of endogenous cortisol secretion, regardless of the 
time of administration.
This lack of effect that ciclesonide has on HPAA function 
has been repeatedly demonstrated in several additional short-
term safety and efﬁ  cacy trials and long-term safety studies 
at doses that are therapeutically effective.
Overall, the observations from these studies demonstrate 
that treatment with ciclesonide in adults appears to achieve 
comparable efﬁ  cacy with a currently available ICS treat-
ment while also reducing systemic activity, as evaluated 
by basal cortisol excretion on HPAA stimulation. Since all 
ICSs deposited in the lungs enter the systemic circulation 
at some stage in the drug’s life-cycle, the lack of effect on 
HPAA function with ciclesonide may be due to its unique 
Table 1 Ciclesonide clinical trials in allergic rhinitis
Author (year) Disease Method Patients Duration Outcomes Results
Ratner (2006b) SAR DBPCR 327 28 days Efﬁ  cacy, safety, 
tolerabily
“Intranasal ciclesonide 
was superior to placebo 
in relieving nasal symp-
toms in[..]conﬁ  rm the 
dose range-ﬁ  nding study 
and support the efﬁ  cacy 
of ciclesonide in AR”
Nave (2006) SAR DBPCR 48 14 days Efﬁ  cacy, safety, 
tolerabiliy
“The low systemic 
exposure and favorable 
safety proﬁ  le support 
the continued clinical 
development”
Ratner (2006a) SAR DBPCR 145 14 days Efﬁ  cacy, safety “200 µg appears to 
be the optimal dose 
studied for reducing the 
symptom of SAR wile 
mantaining an acceptable 
safety proﬁ  le”
Meltzer (2007) PAR DBPCR 471 42 days Efﬁ  cacy, safety “Signiﬁ  cant reductions 
in nasal symptoms and 
appociable improvements 
in health quality of life. 
Ciclesonide was well 
tolerated”
Schmidt (1999) AR DBPCR 24 14 days Efﬁ  cacy, safety, 
tolerabily
“The treatment with 
ciclesonide is effective, 
without producing local 
or systemic side effects”
ALTANA Pharma 
(2006)
SAR PAR 4DBPCR 1524 in 3 trials 3 trials: 2–6 weeks 
1 trial:1 year
Efﬁ  cacy, safety, 
tolerabily
“The results showed that 
patients treated with 
200 µg once daily exhib-
ited statically signiﬁ  cantly 
greater decreases in total 
nasal symptom scores 
than placebo treated 
patients. Measures of efﬁ  -
cacy were also generally 
supportive”
Abbreviations: AR, allergic rhinitis; DBPCR, double blind, placebo-controlled, randomized trial; PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis.Therapeutics and Clinical Risk Management 2008:4(2) 359
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pharmacologic characteristics: the low levels of systemically 
available pharmacologically active desisobutyryl-ciclesonide, 
in addition to rapid elimination and low oral bioavailability, 
may account for the lack of clinically relevant effect that 
ciclesonide has on HPAA function, as evaluated by both 
basal cortisol concentration measurements and dynamic 
stimulation tests (Meltzer and Derendorf 2006).
Adverse effects
In a phase I, single center, randomized, double-blind, placebo-
controlled, multiple-dose, modiﬁ  ed sequential design study, 
healthy volunteers or asymptomatic subjects with a history 
of seasonal allergic rhinitis were randomized to receive 
ciclesonide or placebo via intranasal pump spray for 14 days. 
As expected, intranasal ciclesonide (50–800 µg/day) admin-
istration was generally safe and well tolerated in both healthy 
volunteers and asymptomatic subjects with SAR. An increase 
in the dose of ciclesonide did not correlate with an increase 
in adverse event frequency and the incidence of treatment-
emergent adverse events was comparable between healthy 
volunteers and subjects with SAR. The data are consistent 
with earlier ﬁ  ndings in a 7-day trial of ciclesonide nasal spray 
delivered via a pressurized metered-dose inahaler versus pla-
cebo in subjects with allergic rhinitis, wherein the frequency 
of treatment-emergent adverse events was low and no local or 
systemic side-effects were reported (Nave et al 2006).
A total of 134 treatment-emergent adverse events was 
reported by 41 participants (out of a total of 100 partici-
pants). The most common adverse effects were headache 
(11%), fatigue (7%), and rhinitis (7%). The majority of 
adverse events (97%) were mild in intensity. The frequency 
of adverse events was comparable among healthy volunteers 
and asymptomatic subjects with SAR. The most common 
adverse events considered by the investigator to be possibly 
or probably related to study medication were nose congestion, 
headache, and rhinorrhea. No adverse events were considered 
to be deﬁ  nitely related to the study medication. No serious 
adverse event was reported (Nave et al 2006).
Conclusions
Ciclesonide nasal spray provided substantial symptom relief, 
as measured by patients and physicians. Intranasal admin-
istration of ciclesonide was well tolerated, with an overall 
incidence rate of adverse events comparable with that of 
placebo. The demonstrated efﬁ  cacy and favorable safety and 
tolerability proﬁ  le of ciclesonide suggest that ciclesonide 
nasal spray is an effective treatment option for patients with 
AR (Ratner et al 2006b).
These ﬁ  ndings, in conjunction with the observed clinical 
efﬁ  cacy of ciclesonide, may suggest that ciclesonide has 
an improved therapeutic proﬁ  le and safety compared with 
some other currently available ICS treatments and, therefore, 
the potential to ameliorate adherence rates and therapeutic 
outcomes (Meltzer and Derendorf 2006).
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